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Abstract: Human milk serves as a model for infant formula providing nutritional solutions for
infants not able to receive enough mother’s milk. Infant formulas aim to mimic the composition
and functionality of human milk by providing ingredients reflecting those of the latest human
milk insights, such as prebiotics, probiotics and postbiotics. The aim of this study was to examine
the effects of the supplementation with a postbiotic (LactofidusTM) and its combination with the
prebiotics short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS)
in a preclinical model of healthy suckling rats. Pups were supplemented daily with LactofidusTM
(POST group) and/or scGOS/lcFOS (P+P and PRE groups, respectively). Body weight and fecal
consistency were analyzed. At the end of the study, immunoglobulin (Ig) profile, intestinal gene
expression, microbiota composition and short chain fatty acid (SCFA) proportion were quantified. The
supplementation with all nutritional interventions modulated the Ig profile, but the prebiotic mixture
and the postbiotic induced differential effects: whereas scGOS/lcFOS induced softer feces and
modulated microbiota composition and SCFA profile, Lactofidus™ upregulated Toll-like receptors
gene expression. The use of the combination of scGOS/lcFOS and Lactofidus™ showed the effects
observed for the oligosaccharides separately, as well as showing a synergistic impact on animal
growth. Thus, the combined use of both products seems to be a good strategy to modulate immune
and microbial features in early life.
Keywords: postbiotic; prebiotic; suckling rats; Lactofidus; scGOS/lcFOS; microbiota; SCFA
1. Introduction
Breast milk is the best nutrition for the newborn, and provides all the essential nu-
trients and bioactive compounds such as oligosaccharides (natural prebiotics), immune
cells and bacteria (natural probiotics) and their metabolites (natural postbiotics) in order to
promote his/her development [1,2]. However, in some cases, breastfeeding might not be
possible, and then, an infant formula is the best substitute for breast milk. Thus, manufac-
turers infant formulas aim to mimic the composition of breast milk by adding bioactive
agents to their formulas such as prebiotics, probiotics and more recently, postbiotics [3,4].
Prebiotics are defined as non-digestible compounds that are selectively metabolized
by the microorganisms in the gut, thus modulating the composition and/or activity of the
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gut microbiota, conferring a health benefit on the host [5,6]. In this regard, the short-chain
galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS) mixtures
are the most studied prebiotics in infant formula. [7]. Clinical research has demonstrated
that scGOS and lcFOS supplements change the stool consistency and fecal microbiota
composition making them more similar to that of breastfed infants [7–9]. In addition, during
early life, the incidence of atopic dermatitis, allergy, and infections such as respiratory tract
and gastrointestinal infections in babies fed with this type of infant formula were lower
than those receiving formulas lacking these components [10–16].
Moreover, breast milk is also a source of live bacteria [1,17], thus, probiotic bacteria are
often added to infant formula. Probiotics are defined as live, natural microorganisms, that
when administered in adequate amounts, confer health benefits to the host [18,19]. The
most commonly commercialized probiotic bacteria are strains from the genera Bifidobac-
terium and Lactobacillus [20–22]. Probiotics have the potential to modulate baby’s immune
maturation and even to prevent or treat different diseases such as allergies, type 2 diabetes,
diarrhea, respiratory infections, infant colic, ulcerative colitis, obesity and irritable bowel
syndrome throughout life, their effects being strain specific [10,21,23–25].
Finally, postbiotics are described as a preparation of inanimate microorganisms and/or
their components that confers a health benefit on the host [26]. Postbiotics are a safe and
novel strategy to obtain the beneficial effects of probiotic bacteria without their possible
disadvantages such as the rare case reports of probiotic-related infections and the fact
that probiotics could express virulence factors and transfer antibiotic resistance genes to
pathogenic bacteria in the gut [27–29]. The various procedures (heat, high pressure, ionizing
irradiation or sonication) used to inactivate bacteria affect the microorganisms involved in
the fermentation process differently and can modify the postbiotic composition and the
host’s response to the postbiotic [21,30]. Postbiotics have attractive properties such as a
favorable absorption, distribution and excretion abilities, safety dose parameters and longer
shelf life [31]. Moreover, these properties might indicate a higher capacity to generate
biological responses in different organs and tissues in the host [31]. The effects of specific
postbiotics differ between individuals and also can depend on the temporal changes in gut
microbiota composition [21]. Although the mechanisms of action of postbiotics still remain
unclear [27], postbiotics can change the composition of gut microbiota and their function
and many of their outcomes rely on microbial metabolites, organic acids, carbohydrates,
proteins, lipids, cell wall components and other fermented products generated in the
matrix [21]. Short-chain fatty acids (SCFA) are the major end products of gut microbiota
activity and are associated with healthy gut microbiota composition and function as well
as enhancement of mucosal immunity and intestinal barrier function [2,21]. Some of these
postbiotics, such as the SCFA, are current components present in breast milk [2].
In recent years, the use of postbiotics as a nutritional strategy has increased and their
effects have been studied both at preclinical and clinical levels [21]. It has been observed
that postbiotics are useful in inflammatory diseases such as irritable bowel syndrome,
colitis, gout, arthritis, atopic dermatitis and asthma [21,22,32,33]. Moreover, postbiotics
could prevent or treat infectious diseases such as gastroenteritis, respiratory tract or enteric
infections caused by Escherichia coli or Salmonella enteritidis serovar, Listeria monocytogenes
and Escherichia coli K1 infection [27,34–36]. Finally, other uses of postbiotics could be in
neurological and cardiometabolic disorders [37,38].
For a long time, literature mainly focused on the beneficial effects of prebiotics and
probiotics in infant milk formula, but after the appearance of postbiotics in this field the
advantages compared to probiotics and their many applications have been identified.
Therefore, the present study aimed to examine the effects of a daily supplementation with
a formulation with a postbiotic and prebiotic mixture, as happens in breast milk. The
postbiotic is comprised of an inactivated fermented milk infant formula obtained from
Bifidobacterium breve and Streptococcus thermophilus activity by an innovative fermentation
process (Lactofidus™). Although these microorganisms are not found in breast milk, they
are known to produce 3-galactosyllactose (3-GL), a human milk oligosaccharide (HMO)
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present in breast milk, and frequently used in pediatric population [2]. The prebiotic
is based on a mixture of scGOS and lcFOS. The products alone or in combination were
administered to healthy suckling rats. This study aims to elucidate the specific effects of
this particular postbiotic, but also to ascertain whether its combination with prebiotics,
which is also observed in breast milk, modifies the health outcomes in rat pups. For that,
some growth and immune variables, microbiota composition and SCFA production, among
others, were evaluated.
2. Materials and Methods
2.1. Animals
Pregnant Lewis rats (G14) provided by Janvier (Le Genest St Isle, France) were individ-
ually housed in cages (2184L Eurostandard Type II L, Tecniplast, West Chester, PA, USA),
monitored daily and allowed to deliver at term. The cages contained bedding of large
fibrous particles (Souralit 1035, Bobadeb S.L., Santo Domingo de la Calzada, Spain) and tis-
sue papers (Gomà-Camps S.A.U., La Riba, Spain) as cage enrichment. The day of birth was
registered as day 1 of life. On day 2, litters were randomly assigned to four experimental
groups and were unified to 8 pups per lactating dam with a similar proportion (40–60%)
of each sex in each litter. Pups had free access to maternal milk and rat diet. Dams were
given a commercial diet corresponding to the American Institute of Nutrition 93 G formu-
lation [39] (Teklad Global Diet 2014, Envigo, Indianapolis, IN, USA) and water ad libitum.
Animal handling was performed during the first hours of the light phase on a scheduled
basis, to limit the disturbance and biological rhythms’ influence. After separating all the
mothers and keeping the pups in the home-cage, handling and oral administration was
performed once a day. Afterwards, the dam was reunited with her litter. Animals were
housed under controlled conditions of temperature (20–24 ◦C) and humidity (40–60%) in a
12 h light−12 h dark cycle (lights on at 8:00 a.m and lights off at 8:00 p.m), at the Faculty of
Pharmacy and Food Science animal facility (University of Barcelona, Spain). Cage cleaning
was performed weekly. All experimental procedures were conducted in accordance with
the institutional guidelines for the care and use of laboratory animals and were approved
by the Ethical Committee for Animal Experimentation of the University of Barcelona and
the Catalonia Government (CEEA/Ref. 255/18 and PAMN/Ref.10176, respectively), in
full compliance with national legislation following the EU-Directive 2010/63/EU for the
protection of animals used for scientific purposes. Sample size estimation was calculated by
the Appraising Project Office’s program from the Universidad Miguel Hernández de Elche
(Alicante, Spain). The minimal number of animals to provide statistically significant differ-
ences among groups, using plasma immunoglobulin (Ig) G as a variable and assuming that
there is no dropout rate and type I error of 0.05 (two-sided), was three litters per group, as
in previous studies, because of the remarkable variability among litters [15,40–42].
2.2. Experimental Design and Sample Collection
Upon natural delivery, pups were distributed into four groups of 24 animals each
(3 litters of 8 animals/group): the reference (REF) group and three groups supplemented
with a mixture of scGOS and lcFOS (PRE), LactofidusTM (POST), and the combination of
both (P+P). All supplementations were provided by Danone Nutricia Research (Utrecht,
The Netherlands).
Suckling rats were orally administered once daily, as previously described [10], with
normalized volume/body weight of vehicle, prebiotic, postbiotic or their combination
(9 µL/g/day), from the second to the sixteenth day of life, corresponding to the strict
lactation period. The PRE group was supplemented with 0.8 g of scGOS/lcFOS per 100 g
of body weight. GOS/FOS is a mixture of GOS (Vivinal GOS, Borculo Domo, Zwolle, The
Netherlands) with a degree of polymerisation (dp) of 3–8, and long-chain FOS (Raftiline
HP, Orafti, Wijchen, The Netherlands; average dp > 23) in a 9:1 ratio.
The POST group received 0.92 g/100 g body weight of an infant formula that contained
heat inactivated milk fermented by the bacteria Bifidobacterium breve and Streptococcus ther-
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mophilus (LactofidusTM) [43–46]. Particularly, the LactofidusTM process is a well-controlled
fermentation process in which the two unique and proprietary strains mentioned before
are used to ferment a milk matrix. During fermentation, both strains are metabolically
active and produce bioactive compounds (postbiotics). After the fermentation process the
milk matrix is spray dried and then used in the present study.
The P+P group were fed with both products at the same doses as when given sepa-
rately and maintaining the volume of administration (9 µL/g/day). Finally, a matched
volume of water was administered to the REF group. The product dose selections were
based on previous studies with similar approaches [10,12,41,42,47].
Body weight was recorded daily. Moreover, the naso-anal and tail lengths were mea-
sured to determine the body/tail ratio. In addition, body mass index (BMI) was calculated
as body weight/lenght2 (g/cm2), and the Lee Index was calculated as (weight0.33/length) ×
1000 (g0.33/cm).
During the study, fecal samples were obtained after gentle abdominal massage, to
determine changes in consistency and fecal weight. Stool consistency was scored from 1
to 4 in a blinded manner based on texture and amount as described: normal (1); soft (2);
totally loose (3); and high amount of watery (4) feces. The sampling was performed always
at the same time, after the pups were separated from their mothers and weighted, and
prior to its administration.
Animals were euthanized at two different time points by randomly selecting 4 pups
from each dam maintaining sex equality on each day: half of the litter on day 8 and
the other half on day 16, to obtain tissue samples each time. Rats were intramuscularly
anesthetized with ketamine (90 mg/kg) (Merial Laboratories S.A., Barcelona, Spain) and
xylazine (10 mg/kg) (Bayer A.G., Leverkusen, Germany) and exsanguinated. Plasma
was obtained in order to determine the Ig pattern. The weight of liver, stomach, spleen,
thymus, small intestine and large intestine was also recorded. Moreover, the length of
small and large intestines was measured. Then, a 1 cm central portion of the small intestine
was immediately conserved in RNAlater®(Ambion, Applied Biosystems, Austin, TX,
USA), incubated at 4 ◦C overnight and stored at −20 ◦C until PCR analysis. Moreover,
cecal content was obtained on day 16 for the analysis of the microbiota composition and
SCFA profile.
2.3. pH of Stools and Stomach Content
For pH determination, fecal samples from days 7–9 (middle of the study) and 14–16
(end of the study) were diluted in distilled water (up to 200 mg/mL) and gently agitated
before the measurement. In contrast, stomach content samples from day 8 and 16 were
measured directly without previous dilution. In both cases, pH was measured using
a 5207 pH electrode for surfaces and a micropH 2001 pH meter (Crison Instruments,
Barcelona, Spain).
2.4. Quantification of Immunoglobulins
At the end of the nutritional intervention, on day 16, plasma concentration of IgG1,
IgG2a, IgG2b, IgG2c, IgM and IgA was quantified using ProcartaPlex™ Multiplex im-
munoassay (Thermo Fisher Scientific, Barcelona, Spain) as described in previous stud-
ies [12], in which specific color-coded capture beads were bound to the Ig of interest. Then,
different detection antibodies conjugated to phycoerythrin (PE) were added. The specific
concentration of each analyte was obtained by MAGPIX®analyzer (Luminex Corporation,
Austin, TX, USA) at the Scientific and Technological Centers of the University of Barcelona
(CCiT-UB). The sensitivity of the assay was as follows: 0.02 ng/mL for IgM; 0.78 ng/mL for
IgG1; 0.02 ng/mL for IgG2a; 0.11 ng/mL for IgG2b; 0.19 pg/mL for IgG2c and 0.48 pg/mL
for IgA.
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2.5. Gene Expression Analysis
A 1 cm of a central portion of the small intestine of 16-day-old pups was homogenized
for 30 s in lysing matrix tubes (MP Biomedicals, Illkirch, France) using a FastPrep-24
instrument (MP Biomedicals), as previously described [47]. After RNA isolation with
the RNeasy®Mini Kit (Qiagen, Madrid, Spain) its purity and concentration was deter-
mined with a NanoPhotometer (BioNova Scientific S.L., Fremont, CA, USA). Later, the
corresponding cDNA was obtained using thermal cycler PTC-100 Programmable Ther-
mal Controller and TaqMan®Reverse Transcription Reagents (Applied Biosystems, AB,
Weiterstadt, Germany).
The specific PCR TaqMan®primers (AB) used to assess gene expression with real-
time PCR (ABI Prism 7900 HT, AB) were directed to the detection of IgA (4331348, made
to order), barrier function molecules such as Muc2 (Rn01498206_m1, inventoried [I]),
Muc3 (Rn01481134_m1, I) Ocln (Rn00580064_m1, I) and Cldn2 (Rn02063575_s1, I), Cldn4
(Rn01196224_s1, I) as well as to Toll-like Receptors (TLR), such as Tlr2 (Rn02133647_s1, I),
Tlr3 (Rn01488472_g1, I) Tlr4 (Rn00569848_m1, I), Tlr5 (Rn04219239_s1, I), Tlr7 (Rn01771083_s1,
I), Tlr9 (Rn01640054_m1, I), and maturation markers such as Fcgrt (Rn00583712_m1, I,
encoding for FcRn), and Prdm1 (Rn03416161_m1, I, encoding for Blimp-1). The relative
gene expression was normalized to the housekeeping gene Gusb (Rn00566655_m1, I) using
the 2-∆∆Ct method [48]. Results were expressed as the percentage of expression in each
experimental group normalized to the mean value obtained for the REF group, which was
set at 100%, as in previous studies [40].
2.6. Microbiota Composition
DNA from samples of cecal content collected on day 16 (6 rats/group corresponding
to 2 rats of each of the 3 litters constituting each experimental group) were amplified
25 PCR cycles. A negative control of the DNA extraction was included as well as a positive
Mock Community control to ensure quality control. They were later sequenced in the
V3-V4 variable region of the 16S rRNA gene. The Illumina Miseq sequencing 300 × 2
approach was assessed (Illumina Inc, San Diego, CA, USA) and sequences were merged
and processed using MiSeq run and MiSeq Reporter (on-system software) in collaboration
with (Microomics, Barcelona, Spain).
To estimate the alpha biodiversity, the number of observed operational taxonomic
units (OTUs, i.e., richness), Pielou’s evenness and Shannon’s diversity indexes were cal-
culated and to assess the beta diversity Unweighted Unifrac distance was measured. The
taxonomic assignment of phylotypes was performed using a Bayesian Classifier trained
with Silva database version 132- 99% OTUs full-length sequences [49]. The relative pro-
portions of families and genera were calculated and represented with stacked bars. The
category “others” represented in each graph includes those families whose presence was
lower than 1% in the REF group and those genera whose presence was lower than 3% in
the same group.
In order to study the presence or absence of taxonomic ranks (family and genera) in
the experimental groups, Venn diagrams were created. A bacterial group was considered
as present in the group when all 6 animals displayed proportions higher than 0.001%, while
the bacterial groups detected in less animals were regarded as absent in the group.
2.7. Quantification of Short-Chain Fatty Acids in the Cecal Content
Cecal content samples of 16-day-old suckling rats were acidified in 0.1 M formic acid
and homogenized using Pellet Pestles Cordless Motor (Sigma-Aldrich, Barcelona, Spain)
to reach the concentration of 200 mg/mL to measure cecal SCFA levels by headspace-gas
chromatography-mass spectrometry (HS-GC-MS) at the GC-MS unit of the CCiT-UB, as
previously described [12]. Acetic, propionic, isobutyric, butyric, isovaleric and valeric acids
were quantified. The lower limits of detection (µmol/g of feces) were as follows: 0.404 for
acetic acid, 0.068 for propionic acid, 0.003 for isobutyric acid, 0.020 for butyric acid, 0.001
for isovaleric acid, and 0.001 for valeric acid.
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2.8. Statistical Analysis
Results are expressed as mean ± SEM. The Statistical Package for Social Sciences
(SPSS v22.0) (IBM, Chicago, IL, USA) was used for statistical analysis. Data were tested for
homogeneity of variance and normality distribution by Levene’s and Shapiro–Wilk tests,
respectively. When data were homogeneous and had a normal behavior, conventional
one-way ANOVA test was carried out followed by the post hoc Bonferroni. Otherwise,
the nonparametric Kruskal–Wallis test followed by the post hoc Mann–Whitney U test
was performed. The Spearman correlation coefficient was used to search for correlation
between gut microbiota and SCFA production.
With regard to microbiota composition, alpha diversity comparisons were carried out
using Kruskal–Wallis test. Beta diversity distance matrices were used to calculate principal
coordinates analysis (PCoA) and to make ordination plots using R software package version
3.6.0. Permanova and ANOSIM tests were used to determine the significance of groups
present in community structure. Moreover, Permdisp test was used to identify location
vs. dispersion effects [50]. Differential relative abundance of taxa was tested using two
methods: ANCOM [51] and Kruskal–Wallis test. After Kruskal–Wallis test, Conover’s test
with FDR Benjamini-Hochberg correction was added for pairwise comparison. Finally,
Biodiversity R version 2.11-1, PMCMR version 4.3, RVAide Memoire version 0.9-7 and
vegan version 2.5-5 packages were used for the different statistical analysis preformed.
A principal components analysis (PCA) was performed with Simca v14.1 (Umetrics,
Umea, Sweden) to analyze the natural clustering of samples. Two data matrices consisting
of 40 rows and 8 variables (IgA, IgG, IgG1, IgG2a, IgG2b, IgG2c, IgM and Th1/Th2 ratio)
were constructed in order to analyze the variance observed in the Ig profile, and 34 rows
and 6 variables (TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9) in order to analyze the variance
observed in the TLRs’ expression. Data were represented in score plots. Significant
differences were established when p < 0.05.
3. Results
3.1. Growth and Morphometry
As it can be observed in Figure 1, animals from the P+P group showed higher body
weight than those from the REF, PRE and POST groups (p < 0.05). The highest differences
were observed at the end of the study (day 16), when P+P showed an ~18% increase
compared to the REF group. On day 8, a slightly increase in body weight was observed in
the PRE animals compared to REF ones (p < 0.05). Finally, POST group had similar weights
compared to those of REF (Figure 1). The BMI was not affected due to the diets (Table 1).
Table 1. Growth-associated measurements and relative weight of organs at the end of the study (day 16 of life).
REF PRE POST P+P
Naso-anal (Body, cm) 9.10 ± 0.16 9.44 ± 0.10 9.38 ± 0.10 9.75 ± 0.07 *# ϕ
Anus-tail (Tail, cm) 4.78 ± 0.11 4.58 ± 0.07 5.00 ± 0.07 # 4.99 ± 0.07 #
Naso-tail (cm) 13.88 ± 0.24 14.03 ± 0.16 14.38 ± 0.08 14.74 ± 0.13 *# ϕ
Body/Tail length ratio 1.91 ± 0.03 2.06 ± 0.02 * 1.88 ± 0.04 # 1.96 ± 0.02 #
Body mass index (g/cm2) 0.32 ± 0.01 0.32 ± 0.00 0.33 ± 0.01 # 0.34 ± 0.00 #
Lee index (g0.33/cm, ×1000) 327.35 ± 2.53 321.97 ± 1.00 * 329.16 ± 2.78 327.21 ± 1.42 #
Spleen/BW ratio (%) 0.43 ± 0.03 0.47 ± 0.02 0.47 ± 0.02 0.49 ± 0.02
Thymus/BW ratio (%) 0.45 ± 0.01 0.44 ± 0.01 0.45 ± 0.01 0.45 ± 0.01
Liver/BW ratio (%) 3.40 ± 0.05 3.47 ± 0.06 3.42 ± 0.10 3.54 ± 0.08 *
Large int./BW ratio (%) 0.60 ± 0.01 0.71 ± 0.02 * 0.57 ± 0.02 # 0.68 ± 0.02 * ϕ
Small int./BW ratio (%) 3.48 ± 0.09 5.32 ± 0.09 * 3.45 ± 0.07 # 5.06 ± 0.15 * ϕ
Large int. length/BW (cm/g) 24.91 ± 1.48 22.78 ± 0.77 21.63 ± 1.28 20.41 ± 0.54 *#
Small int. length/BW (cm/g) 134.96 ± 6.49 142.73 ± 6.53 127.35 ± 2.86 # 120.41 ± 5.72 #
Stomach/BW ratio (%) 0.76 ± 0.02 0.75 ± 0.02 0.70 ± 0.01 # 0.71 ± 0.01
Relative weight of organs was expressed as percentage (%) with respect to the body weight (BW) and growth-associated measurements are
expressed as mean ± SEM (n = 8–12). Statistical significance: * p < 0.05 vs. REF, # vs. PRE and ϕ vs. POST. REF: reference group; PRE:
group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P: group supplemented with
the combination of both.
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vs. REF, δ P+P vs. PRE and ε P+P vs. POST. REF: reference group; PRE: group supplemented with a 
mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P: group supple-
mented with the combination of both. 
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Some differences were observed in the naso-anal, naso-tail, body/tail length ratio and 
Lee index on day 16 (Table 1. On day 16, prebiotic and postbiotic supplementation in-
creased the naso-anal and the naso-tail measures compared to REF, PRE and POST ani-
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compared to REF, POST and P+P (p < 0.05) and a lower Lee index compared to REF group 
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group showed a ~5% increase in naso-anal length and a ~2% reduction in Lee index com-
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Figure 1. i t f pups (g) during the study (from day 2 to day 16 of life). Results are
expressed as mean ± SEM (n = 24 animals/group). Statistical differences: α p < 0.05 PRE vs. REF, β
P+P vs. REF, δ P+P vs. PRE and ε P+P vs. POST. REF: reference group; PRE: group supplemented
with a mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P: group
supplemented with the combination of both.
Some diff rences were obs rved in the n so-anal, naso-tail, bod /tail length ratio
and Lee index on day 16 (Table 1. On day 16, prebiotic and postbiotic supplementation
increased the naso-anal and the naso-tail measures compared to REF, PRE and POST
animals (p < 0.05) (Table 1). Moreover, the PRE group showed a higher body/tail length
ratio compared to REF, POST and P+P (p < 0.05) and a lower Lee index compared to
REF group (p < 0.05). No differences were observed in the POST group compared to
REF animals.
In addition, on day 8, some of these changes were already present. Specifically, POST
group showed a ~5% increase in naso-anal length and a ~2% reduction in Lee index
compared to REF animals p < 0.05). P+P group had also a higher naso-anal length (~3.5%)
and body/tail length ratio (~6%) compared to REF group (p < 0.05) and the Lee index was
also higher (~2.5%) than that in the POST group (321.49 ± 1.72; p < 0.05).
With regard to organ weights, as it can be observed in Table 1, on day 16, PRE and P+P
groups showed a higher relative weight of the large and small intestine compared to REF
and POST animals (p < 0.05). In addition, P+P group showed a higher relative weight of
the liver and a lower large intestine length/weight ratio compared to REF group (p < 0.05).
No differences were observed in the POST group compared to REF animals (Table 1).
On day 8, after a few days of supplementation, other changes also appeared. A ~20%
increase in spleen relative weight was observed in PRE and P+P groups (compared to REF
animals (p < 0.05). In addition, PRE group showed a 9–40% lower relative weight increase
in liver compared to REF, POST and P+P animals p < 0.05), whereas in POST group it was
higher compared to REF. All supplemented groups showed an increase in the relative small
intestine weight, especially P+P group, which showed the highest value compared to all
groups (p < 0.05), whereas POST showed the lower value of the supplemented groups
(p < 0.05). In addition, P+P animals showed a 25% reduction in the length/weight ratio of
the large intestine with respect to REF ones (p < 0.05).
Only on day 16, the POST group showed higher platelets count compared to REF
and PRE animals (p < 0.05), whereas PRE group showed a lower hematocrit compared to
REF group (p < 0.05). P+P group had a reduction in the mean cell volume of erythrocytes
compared to REF and POST animals (p < 0.05) (Supplementary Table S1). On day 8,
the hematological variables in all supplemented groups were similar to REF ones (data
not shown).
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3.2. Fecal and Stomach Content Variables
Stool samples were collected and scored (scale 1–4) daily during all the studied period.
The PRE and P+P supplementations induced changes in fecal consistency increasing the
number of soft feces (p < 0.05). In contrast, the supplementation with the postbiotic did not
affect the stool score (Figure 2a).
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Figure 2. Fecal consistency during the study (from day 4 to day 16 of life) (a) and mean fecal weight from day 4 to day 7
(first week) and from day 8 to day 16 (second week) (b), fecal p (on days 7–9 and 14–16) (c), and stomach content pH (on
day 8 and 16) (d). Results are expressed as ean SE (n 12–24 ani als/gro p). Statistical differences: α p < 0.05 PRE
vs. REF, β P+P vs. REF, λ POST vs. PRE, δ P+P vs. PRE and ε P+P vs. POST (a), * vs. REF, # vs. PRE and φ vs. POST (b–d).
REF: reference group; PRE: group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented with
LactofidusTM; P+P: group supplemented with the combination of both.
As it can be observed in Figure 2b, during the first (from day 4 to day 7) and second
(from day 8 to day 16) week of life, PRE and P+P groups had a higher fecal weight compared
to REF and POST animals (p < 0.05). POST group showed similar fecal weight compared
to REF ones, however, a tendency to increase the fecal weight was observed during the
second week (p = 0.05).
The fecal pH and the stomach content pH were also measured (Figure 2c,d, respec-
tively). P+P showed a higher fecal pH compared to PRE and POST groups at days 14–16
(p < 0.05). No differences in the fecal pH were observed between any of the supplemented
groups and the REF animals, although a tendency to reduce the fecal pH in the PRE group
was observed (p = 0.09) on days 7–9 and a tendency to increase the fecal pH in the P+P
group was observed on days 14–16 (p = 0.08) (Figure 2c). Moreover, on day 8, PRE and P+P
groups showed a reduction in the pH of the stomach content compared to REF animals
(p < 0.05, Figure 2d).
3.3. Immunoglobulins in Plasma
Plasma concentrations of IgG, IgM and IgA isotypes, IgG subclasses, as well as the
Th1/Th2 ratio were quantified at the end of the study (day 16, Table 2).
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Table 2. Concentration of immunoglobulins in plasma at the end of the study (day 16).
Ig (µg/mL) REF PRE POST P+P
IgG 3117.81 ± 271.58 2968.14 ± 194.43 2341.86 ± 202.01 * 1985.85 ± 110.81 *#
(98.64 ± 0.04%) (98.52 ± 0.03% *) (98.47 ± 0.06% *) (98.41 ± 0.05% *)
IgG1 260.53 ± 25.42 208.69 ± 14.56 142.05 ± 15.73 *# 130.10 ± 8.56 *#
(8.97 ± 1.06%) (7.02 ± 0.11%) (6.07 ± 0.42%) (6.56 ± 0.23%)
IgG2a 551.53 ± 38.91 499.33 ± 28.96 394.47 ± 31.40 *# 363.66 ± 19.07 *#
(18.01 ± 0.65%) (17.35 ± 1.27%) (17.01 ± 0.79%) (18.49 ± 0.69%)
IgG2b 1193.30 ± 109.62 1255.98 ± 93.37 813.73 ± 78.19 *# 758.59 ± 46.86 *#
(38.12 ± 0.45%) (42.11 ± 0.65% *) (34.61 ± 0.66% *#) (38.15 ± 0.88% #ϕ)
IgG2c 1112.44 ± 131.36 1004.12 ± 84.37 991.60 ± 87.20 733.49 ± 52.67 *#ϕ
(34.91 ± 1.21%) (33.52 ± 0.94%) (42.30 ± 0.35% *#) (36.79 ± 1.39% ϕ)
IgM 23.02 ± 1.55 26.86 ± 2.18 23.21 ± 3.14 20.46 ± 1.23 #
(0.74 ± 0.02%) (0.89 ± 0.03% *) (0.96 ± 0.07% *) (1.02 ± 0.04% *#)
IgA 18.97 ± 1.05 17.68 ± 0.76 13.30 ± 0.81 *# 11.61 ± 0.96 *#
(0.62 ± 0.02%) (0.6 ± 0.02%) (0.57 ± 0.02%) (0.57 ± 0.02%)
Th1/Th2 ratio a 2.81 ± 0.20 3.20 ± 0.22 * 3.34 ± 0.08 * 3.03 ± 0.14
The percentage of 100% of the isotypes corresponds to the sum of IgG + IgM + IgA and the percentage 100% of the subtypes of IgG
corresponds to the sum of IgG1 + IgG2a + IgG2b + IgG2c. Results were expressed as mean ± SEM (n = 8–12). Statistical significance:
* p < 0.05 vs. REF, # vs. PRE and ϕ vs. POST. a Th1/Th2 ratio refers to the relationship between IgG2b + IgG2c: IgG1+IgG2a. REF:
reference group; PRE: group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P: group
supplemented with the combination of both.
PRE group showed an increase in the percentage of IgM caused by a reduction in that
for IgG (p < 0.05), although the percentage of IgG2b subclass was higher compared to REF
animals (p < 0.05). POST group showed a higher percentage of IgM whereas the levels
of IgA, IgG and the subclasses IgG1, IgG2a, IgG2b were lower compared to REF group
(p < 0.05). Moreover, although the percentage of IgG and IgG2b were reduced (p < 0.05),
the proportion of the IgG2c subclass was higher (p < 0.05) in animals from POST group
than in REF animals. Finally, in line with the POST group, a higher percentage of IgM and
a reduction in IgA, IgG, IgG1, IgG2a, IgG2b, IgG2c levels were observed in the P+P group
compared to REF (p < 0.05). Overall, the PRE and POST groups showed a higher Th1/Th2
ratio. The Ig profile between supplemented groups was also different. POST and P+P
groups displayed lower levels of IgA, IgG1, IgG2a and IgG2b compared to PRE (p < 0.05).
The percentage of IgG2b was lower in POST group whereas IgG2c was higher compared
to PRE animals. On the other hand, P+P showed lower levels of IgG and IgM whereas
the percentage of IgM increased compared to PRE group (p < 0.05) and the levels of IgG2c
decreased compared to PRE and POST groups and the percentage of IgG2b was higher
compared to POST (p < 0.05). The overall impact of the diets on the Ig pattern, is clearly
observed in a PCA representation: the POST and P+P groups were clustered differently to
REF, whereas the PRE group was intermediately distributed (Supplementary Figure S1a).
3.4. Gene Expression
The gene expression of molecules involved in the intestinal barrier capacity (mucin
[MUC] 2, MUC3, claudin [Cldn] 2, Cldn4 and occludin [Ocldn]), intestinal immunity (IgA,
FcRn and Blimp-1), and microbiota-host signaling receptors (TLR 2, 3, 4, 5, 7 and 9) were
measured at the end of the supplementation period (on day 16) (Figure 3).
The gene expression of MUC2 was lower in the PRE group compared to REF and
POST animals (p < 0.05. Figure 3a). As it can be observed in Figure 3b, the levels of MUC3
were higher in P+P group compared to REF and POST group (p < 0.05). Although no
differences were observed in the expression of Cldn2, Cldn4 and Ocldn, in the P+P group
there was a tendency to increase the levels of Cldn 4 (×1.5 times; p = 0.07) compared to
REF animals (Figure 3c–e).
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Figure 3. Relative gene expression of mucin (MUC) 2 (a) and MUC 3 (b), tight junction proteins claudin (Cldn) 2, Cldn4
(c,d, respectively) and occludin (Ocldn) (e), immunity related molecules IgA (f), FcRn (g) and Blimp-1 (h) and Toll-like
receptors (TLR) 2 (i), TLR3 (j), TLR4 (k), TLR5 (l), TLR7 (m) and TLR9 (n) was quantified by real-time PCR on day 16.
Relative gene expression was calculated with respect to REF animals, which corresponded to 100% of transcription. Results
are expressed as mean ± S.E.M. (n = 8–9 animals/group). Statistical significance: * p < 0.05 vs. REF, # vs. PRE and φ vs.
POST. REF: reference group; PRE: group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented
with LactofidusTM; P+P: group supplemented with the combination of both.
With regard to the expression of molecules involved in the immune system maturation
and functionality, no differences were observed in the levels of IgA, FcRn and Blimp-1
(Figure 3f–h). However, POST group showed a tendency to increase the expression of IgA
compared to REF group (×1.8 times; p = 0.07).
Finally, POST group showed higher levels of TLR2, TLR3 and TLR9 compared to
REF animals being 1.5 times higher than REF animals (p < 0.05) and higher levels of TLR4
compared to PRE group (×1.7 times; p < 0.05). In addition, an increase in the expression of
TLR2, TLR3, TLR5, TLR7 and TLR9 (×1.4–1.8 times) was observed in P+P group compared
to REF group (Figure 3i–n) and higher levels of TLR3 compared to PRE group (×1.4 times;
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p < 0.05). No differences were observed in the PRE group, although, a tendency to increase
the levels of TLR2 was observed (1.5 times; p = 0.07). Thus, it seems that most of the effects
of the postbiotic are maintained in the mixture, as it can be observed in the PCA from
Supplementary Figure S1b, in which the POST and P+P groups showed a cluster that
differed from that of the REF; in contrast, PRE group formed an intermediate cluster.
3.5. Microbiota
The cecal microbiota composition was analyzed on day 16 (Figure 4). The alpha diver-
sity of microbial populations was assessed by richness, Pielou’s evenness and Shannon’s
indexes. The group supplemented with the postbiotic had a higher richness compared
to REF, PRE and P+P animals (p < 0.05; Figure 4a) and a higher Shannon’s index com-
pared to P+P group (p < 0.05), whereas the PRE group showed a lower Pielou’s evenness
(Figure 4b) compared to REF and a reduced Shannon’s (Figure 4c) index compared to REF
and POST group (p < 0.05). The beta diversity calculated by measuring the Unweighted
Unifrac distance (Figure 4d) showed that the POST group formed a cluster appart from the
other groups.
The proportion of bacteria at the family level was different between groups. The rats
supplemented with the prebiotic and with the combination of prebiotic and postbiotic
showed a lower relative abundance of Akkermansiaceae and higher levels of Clostridiaceae
1 compared to REF animals (p < 0.05) and the levels of Clostridiaceae 1 in P+P group were
also higher compared to POST group (p < 0.05). In addition, the relative abundance of
Peptostreptococcaceae were increased in PRE group compared to REF and POST animals
(p < 0.05) (Figure 4e). POST group showed lower levels of Enterobacteriaceae compared
to PRE and P+P animals (p < 0.05). The minority families together constituting the group
“others”, displayed some differences when analysed separately. Four rats from PRE group
showed some levels of Bifidobacteriaceae (0.21 ± 0.11) compared to REF and POST group
which did not have detectable values of this family in any animal (p < 0.05) confirming
the bifidogenic effect of this prebiotic. In addition, the Chitinophagaceae proportion was
lower in samples from POST group compared to those from the REF group (0.01 ± 0.01
and 0.11 ± 0.04, respectively; p < 0.05).
In order to gain a deeper understanding of the presence or the absence of bacterial
groups after the different supplementations, Venn diagrams were created. The Venn di-
agrams were restrictive, and only when all the animals of the group had a count of that
bacterial family, this family was considered to be present in the group. Therefore, Muribac-
ulaceae and Prevotellaceae were only present in the POST group and Clostridiaceae 1 was
present only in the P+P group. All the groups supplemented with the prebiotics, postbiotic
or both of them, but not the REF group, showed the presence of the Peptostreptococcaceae
and Burkholderiaceae families (Figure 4f).
The proportion of the majority genera was not statistically different between groups
except for the reduction observed in the Akkermansia genus in the groups PRE and P+P
compared to REF animals (p < 0.05) (Figure 4g). In the minority genera, no Bifidobacterium,
Tyzzerella 3, Turicibacter and Enterobacter were found in REF nor POST, however some
animals in the PRE group (four animals in Bifidobacterium, Tyzzerella 3 and Turicibacter
and five animals, in Enterobacter) showed these genera (0.22± 0.12, 0.85± 0.40, 0.08 ± 0.03
and 0.11 ± 0.03, respectively; p < 0.05). Romboutsia abundance was higher in PRE and
P+P group (3.31 ± 0.43, 3.81 ± 0.69, respectively) compared to REF group (1.58 ± 0.28;
p < 0.05), whereas in POST group Romboutsia abundance was lower compared to the
other groups (0.44 ± 0.05; p < 0.05). Vibrionimona proportions were reduced in POST
compared to REF group (0.01 ± 0.01 and 0.12 ± 0.05, respectively; p < 0.05). In contrast to
REF, PRE and P+P groups, Eubacterium nodatum group was found only in four animals
from the POST group (0.27 ± 0.09; p < 0.05). The relative abundance of Clostridium
ASF356 was higher in POST (0.70 ± 0.18) group compared to P+P animals (0.01 ± 0.01;
p < 0.05). No animal from REF and PRE group showed levels of Clostridium ASF356.
POST group had an increase in Faecalibacterium UBA1819 (1.35 ± 0.59) compared to PRE
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animals (0.03 ± 0.02; p < 0.05). No animal from REF and P+P groups showed levels of
Faecalibacterium UBA1819. Anaerotruncus increased its proportion in P+P (8.36 ± 1.01)
compared to REF group (2.91 ± 0.94, respectively; p < 0.05).
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Regarding the Venn diagram information, POST group had the exclusive presence
of the genera Erysipelatoclostridium, Lachnoclostridium, Lachnoclostridium 5, Lachno-
clostridium 9 and Prevotellaceae UCG-001. Moreover, P+P group was the only one that
showed Clostridium sensu stricto 1. Finally, Parasutterella was observed in the animals
supplemented with all the products tested but not in the REF group (Figure 4h).
3.6. Cecal SCFA Production
The amount of total SCFA and acetic, propionic, isobutyric, butyric, isovaleric and
valeric acid proportion in the cecum of the suckling rats were measured at the end of the
study (Figure 5).




Figure 5. SCFA production in cecal samples of 16-day-old suckling rats. Total SCFA (a), acetic (b), propionic (c), butyric 
(d), isobutyric (e), isovaleric (f) and valeric (g) acid proportion (µmol/g of cecal content). Results are represented as mean 
± SEM (n = 8–12 samples/group). Statistical significance: * p < 0.05 vs. REF, # vs. PRE and ϕ vs. POST. REF: reference group; 
PRE: group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P: group 
supplemented with the combination of both. 
The total SCFA levels in the caecum was similar between groups (Figure 5a). How-
ever, the percentage of acetic acid was higher in PRE and P+P groups compared to REF 
and POST animals (p < 0.05) (Figure 5b). On the other hand, the proportion of propionic, 
isobutyric and isovaleric acids was lower in PRE and P+P groups compared to those in 
the REF and POST groups (p < 0.05). No differences were observed in the percentages of 
butyric and valeric acids between groups. 
The acetic acid levels correlated positively with the relative proportion of Clostridi-
aceae 1 (r = 0.80, p < 0.05) (Clostridium sensu stricto 1 genus) Bifidobacteriaceae (r = 0.43, 
p < 0.05) (Bifidobacterium genus), Peptostreptococcaceae (r = 0.78, p < 0.05) and Enterobac-
teriaceae (r = 0.68, p < 0.05) families and negatively with Akkermansiaceae (r = −0.56 p < 
0.05), Lachnospiraceae (r = −0.57, p < 0.05) Family XII (r = −0.49 p < 0.05), Muribaculaceae 
(r = −0.70 p < 0.05) and Prevotella (r = −0.69 p < 0.05) families. With regard to the propionic 
acid levels, a positive correlation was observed with the relative proportion of Akkerman-
siaceae (r = 0.56, p < 0.05), Prevotella (r = 0.69, p < 0.05), Family XII (r = 0.49, p < 0.05), 
Muribaculaceae (r = 0.62, p < 0.05) and Lachnospiraceae (r = 0.55, p < 0.05) families, whereas 
Clostridiaceae 1 (r = −0.80, p < 0.05), Enterobacteriaceae (r = −0.70, p < 0.05) Bifidobacteri-
aceae (r = −0.43, p < 0.05) and Peptostreptococcaceae (r = -0.72, p < 0.05) showed a negative 
correlation. Butyric acid correlated positively with Eggerthellaceae (r = 0.62, p < 0.05). Iso-
butyric acid correlated positively with the relative abundance of Akkermansiaceae (r = 
0.58 p < 0.05) and isobutyric and isovaleric acids correlated negatively with Enterobacte-
riaceae (r = −0.67 and r = −0.55, respectively; p < 0.05) and Clostridiaceae 1 family abun-
dance (r = −0.73 and r = −0.70, respectively; p < 0.05) whereas Muribaculaceae (r = 0.61 and 
r = 0.49, respectively; p < 0.05) Lachnospiraceae (r = 0.50 and r = 0.64, respectively; p < 0.05) 
and Prevotella (r = 0.53 and r = 0.49, respectively; p < 0.05) were correlated positevely (Sup-
plementary Figure S2). 
4. Discussion 
There is evidence supporting the beneficial effects of prebiotics, postbiotics and pro-
biotics, modulating the gut microbiota [11,20,35,37]. Formulas with postbiotics and prebi-
otics have been shown to support normal infant growth and are safe and well-tolerated 
in healthy infants [45,52,53]. In addition, prebiotics and probiotics have been demon-
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Figure 5. S F production in cecal sa ples of 16-day-old suckling rats. Total S F (a), acetic (b), propionic (c), butyric
(d), isobutyric (e), isovaleric (f) and valeric (g) acid proportion (µmol/g of cecal content). Results are represented as
mean ± SEM (n = 8–12 samples/group). Statistical significance: * p < 0.05 vs. REF, # vs. PRE and φ vs. POST. REF: reference
group; PRE: group supplemented with a mixture of scGOS and lcFOS; POST: group supplemented with LactofidusTM; P+P:
group supplemented with the combination of both.
The total SCFA levels in the caecum was similar between groups (Figure 5a). However,
the percentage of acetic acid was higher in PRE and P+P groups compared to REF and
POST animals (p < 0.05) (Figure 5b). On the other hand, the proportion of propionic,
isobutyric and isovaleric acids was lower in PRE and P+P groups compared to those in
the REF and POST groups (p < 0.05). No differences were observed in the percentages of
butyric and valeric acids between groups.
The acetic acid levels correlated positively with the relative proportion of Clostridi-
aceae 1 (r = 0.80, p < 0.05) (Clostridium sensu stricto 1 genus) Bifidobacteriaceae (r = 0.43,
p < 0.05) (Bifidobacterium genus), Peptostreptococcaceae (r = 0.78, p < 0.05) and Enterobac-
teriaceae (r = 0.68, p < 0.05) families and negatively with Akkermansiaceae (r = −0.56,
p < 0.05), Lachnospiraceae (r = −0.57, p < 0.05) Family XII (r = −0.49 p < 0.05), Muribac-
ulaceae (r = −0.70 p < 0.05) and Prevotella (r = −0.69 p < 0.05) families. With regard to
the propionic acid levels, a positive c rrelation as observed with the relative proportion
of Akkermansiaceae (r = 0.56, p < 0.05), Prevotella (r = 0.69, p < 0.05), Family XII (r = .49,
p < 0.05), Muribaculaceae (r = 0.62, p < 0.05) and Lachnospiraceae (r = 0.55, p < 0.05) fami-
lies, whereas Clostridiaceae 1 (r = −0.80, p < 0.05), Ent robacteriaceae (r = −0.70, p < 0.05)
Bifidobacteriaceae (r = −0.43, < 0.05) and Peptostreptococcaceae (r = -0.72, p < 0.05)
showed a negative correlation. Butyr c acid correlated positively with Eggerthellaceae
(r = 0.62, p < 0.05). Isobutyr c acid correlated positively with the relative bund nce of
Akkermansiaceae (r = 0.58 p < 0.05) and isobutyric and isovaleric c ds correlated negatively
with Enterobacteriaceae (r = −0.67 and r = −0.55, respectively; p < 0.05) nd Clostridiaceae
1 family abund ce (r = − .73 and r = −0.70, respectiv ly; p < 0.05) wh r as Murib cu-
laceae ( = 0.61 and r = 0.49, respectively; p < 0.05) Lachnospiraceae (r = 0.50 and r = 0.64,
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respectively; p < 0.05) and Prevotella (r = 0.53 and r = 0.49, respectively; p < 0.05) were
correlated positevely (Supplementary Figure S2).
4. Discussion
There is evidence supporting the beneficial effects of prebiotics, postbiotics and probi-
otics, modulating the gut microbiota [11,20,35,37]. Formulas with postbiotics and prebiotics
have been shown to support normal infant growth and are safe and well-tolerated in healthy
infants [45,52,53]. In addition, prebiotics and probiotics have been demonstrated to result in
stool consistency and frequency closer to breast-fed infants. Moreover, decreasing stool pH,
increasing SCFA and modulating gastrointestinal microbiota towards a breast-fed infant
profile [21,54,55]. In this study, we analysed the effects of a postbiotic (Lactofidus™) and
its combination with a prebiotic mixture usually used in infant formulas (scGOS/lcFOS) in
suckling rats, as a preclinical model for studying the immune system maturation.
In our study, the P+P group, but not the prebiotic or the postbiotic alone, showed a
consistent higher growth rate during the suckling period compared to REF animals. In
previous studies using this animal model, the administration of the same prebiotic mixture
of scGOS/lcFOS alone—without the postbiotic—also showed this lack of effect on body
weight [10] or just a slight increase at the end of suckling period [12]. Additionally, Morel
F.B et al. did not observe an effect on growth and body weight of pre-weaning rats after
GOS-Inulin supplementation [56]. With regard to humans, whereas a supplementation
with GOS-FOS in early life showed an increase in the body weight and length of infants [13],
other studies did not find these effects [9,45]. Focusing on the impact of the postbiotics
used alone in growing infants, no effect has been previously observed [4]. In line with this,
the studies evaluating infant weight/growth using a combination of scGOS/lcFOS with
Lactofidus™ also demonstrated adequate growth [52] or even an impact on the infant’s
length [57]. The possible rationale for this growth promoting effect in this preclinical study
only when scGOS/lcFOS and the postbiotic are combined may involve a potentiation effect
of the postbiotic on the well described capacity of oligosaccharides to increase intestinal
calcium absorption [58–60].
It is widely known that scGOS/lcFOS mixture can prevent constipation that can occur
in formula-fed infants by inducing a softer stool consistency and making it more similar
to that of breastfed infants [9,54,57]. This feature of softer stools is also observed in our
study after the PRE administration. In contrast, the postbiotic supplement alone did not
affect the stool consistency. However, the combination of both compounds maintained the
consistency observed in the PRE group. In this regard, besides the literature reporting this
effect by the prebiotic mixture scGOS/lcFOS [9,21,55,61] it has been shown that the infant
formula enrichment with Lactofidus™ combined with scGOS/lcFOS also induces softer
stool consistency [46,52]. Same effect was confirmed by Huet F. et al., who also observed
that infant’s fecal consistency after Lactofidus™ supplementation was higher compared to
scGOS/lcFOS alone or scGOS/lcFOS combined with different percentages of Lactofidus™
(15% or 50%) [57].
Changes in stool consistency may be accompanied by an increase in fecal water and
pH alterations. However, in our study the fecal pH was not significantly affected by any
of the interventions compared to that in non-supplemented animals, although the PRE
supplementation had a tendency to reduce the fecal pH during the first week. Previous
studies in our group with this same prebiotic mixture in suckling rats, although under
an infective process, showed some acidification effect [42]. In humans, some studies also
observed that scGOS/lcFOS supplementation reduced the fecal pH [9,52,61]. Huet F. et al.
reported that the infant formula supplemented with Lactofidus™ induced an increase in
the fecal pH [57] whereas Béghin L. et al. observed that fecal pH was lower in infants
that received infant formula containing scGOS/lcFOS with or without a postbiotic [52].
Moreover, during the first week in our study, the prebiotic and also its combination with
the postbiotic induced a reduction in the stomach content pH. Very few data are available
regarding the effect of these compounds in this compartment neither in animals nor humans.
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The result reported here could suggest a positive effect on the prevention of pathogen entry
into the gastrointestinal tract as it occurs in the case of the lower fecal pH [61,62].
The Ig profile changed in all supplemented groups, higher IgM proportion and lower
IgG levels were observed leading to an increase in the Th1/Th2 ratio. During the first
weeks of life, the main circulating Ig are maternal IgG which are even in higher levels than
the developing infant production of IgG and IgM and finally IgA [63]. Despite the lower
levels of IgG, the increase in the proportion of IgM due to the prebiotic, postbiotic and its
combination administration in early life could indicate a positive effect on the maturation
of the immune system. In addition, after all supplementations an increase in an isotype
associated with the Th1 response (rat IgG2b) and a decrease in an isotype associated with
the Th2 response (rat IgG1) thus leading to a Th1 promoting effect was also observed,
thereby suggesting again an enhancement of the immune system maturation. This effect on
Th1 response is also observed at the end of suckling period in a model of rotavirus infection
in rats supplemented with the scGOS/lcFOS mixture [12]. In humans, the Th1/Th2 IgG
subclasses are different from rats whereas IgG1, IgG2 and IgG3 are associated with a Th1
response, IgG4 is related to a Th2 response. Van Hoffen E. et al. observed that infants at
risk for allergy fed with infant hypoallergenic whey formula enriched in scGOS/lcFOS,
or in maltodextrin for comparison, had a significant reduction in the Th1 associated IgG
subclasses (i.e., IgG1, IgG2 and IgG3 for human) [64]. To our knowledge, this is the first
report of a postbiotic intervention indicating changes in the Ig profile similar to that induced
by a prebiotic intervention.
Intestinal mucins have a role in the innate defense through the limitation and the
neutralization of invasive pathogens [65]. The two most abundant intestinal mucins are the
secretory MUC2 and the membrane bound MUC3 [66]. The prebiotic intervention induced
a reduction in the levels of MUC2 gene expression, in agreement with a reduction also
observed in a gastrointestinal infection model in suckling rats supplemented with this
prebiotic mixture [12]. However, both rat and mice supplementation with GOS or FOS later
in life, did not allow to observe this effect on MUC2 [67,68]. Akkermansia species are mucin
degrading intestinal bacteria [69], thus a possible explanation for the reduction in MUC2 in
this study after the scGOS/lcFOS intervention could be the reduction in Akkermansiaceae
family observed in the PRE group. In this regard, in the PRE group could not need to
continuously replace the mucus layer because there were less Akkermansia using mucus as
energy source. Alternatively, the combination of the prebiotics with the postbiotic (P+P
group) increased the MUC3 gene expression levels, suggesting a reinforcement in the
innate barrier function of the suckling rats. In this regard, although it has been described
that rats supplemented with GOS or FOS do not show differences in the expression of
MUC3 [67], there is no available literature regarding the influence of a postbiotic alone or
in combination.
Tight junction proteins have an important role in the intestinal barrier function regu-
lating the permeability of molecules and acting as a physical barrier [70]. After the different
supplementations, no differences were observed in their gene expression which differs com-
pared to other studies evaluating GOS supplementation effect on the jejunum of piglets [71].
In addition, the expression of the genes FcRn, IgA and Blimp, which are related to the
immune maturation and regulation, was not modified due to the interventions. However,
the intestinal gene expression of the TLRs, which play a role in sensing pathogen-associated
molecular patterns and contributing to eliminate pathogens and establishing the adaptative
immunity [72], were highly modulated by the postbiotic intervention, and its combination
with the prebiotic mixture. Upregulation of TLR2, TLR3 and TLR9 gene expression due
to the postbiotic intervention was observed in the combination of the postbiotic and the
prebiotic. In addition, only the combination was able to induce the increase in TLR5 and
TLR7 expression, indicating that both types of compounds acting together are required
to induce such an effect. To our knowledge, there is no literature about the expression
of these genes after supplementation of a postbiotic alone or in combination with? in
healthy rats or infants. However, this enhancement may suggest that the postbiotic, alone
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or in combination, can prepare the intestinal immune system for a better response against
infections by strengthening the microorganism-host interaction.
In addition to the impact of these supplements on the immune system of the suckling
rats, the microbiota composition and its functionality was evaluated. Although the number
of samples per group (N = 6) could have been increased for clearer results, we found that
the alpha diversity of microbial populations was able to be measured by three indexes,
and whereas the intervention with the postbiotic induced a higher richness or number of
observed OTUs, the prebiotic intervention led to lower Pielou’s and Shannon’s indexes,
indicating lower overall biodiversity or lower equity in community proportion distribution.
Although a FOS intervention in piglets affected diversity [73], very little is known about
the postbiotics, in preclinical models or humans in this regard. Moreover, specific changes
in microbial composition due to the interventions were observed in the PRE and the
P+P group. The postbiotic alone did not change the microbial composition, however
in combination it maintained the changes induced by the prebiotic supplementation in
addition to some other slight differences. In this regard, the PRE and P+P groups showed
a lower abundance of Akkermansiaceae family and Akkermansia genus compared to REF
animals. Akkermansia muciniphila belongs to Akkermansiaceae family and this specie has
been associated with health and inversely correlated to different diseases such as colitis
and Crohn’s disease [74] or even Parkinson [75]. The reduction in the abundance of this
bacterium could be due to the lower expression of MUC2 in both groups, specially the
scGOS/lcFOS group. This reduction could decrease the formation of mucus and therefore
the bacterium would have less substrate for growing.
Moreover, some animal studies have demonstrated the promoting effect of FOS on
Akkermansia muciniphila growth [76], thus the combination with GOS or the postbiotic and
the early age could have a role in our differential result. In addition, some studies also
showed an inverse correlation of A. muciniphila abundance with body weight [77,78], a fact
that could be also involved in the growth promoting effect observed in P+P supplemented
animals in our study. In addition, our results showed that all the interventions promoted
the presence of Peptostreptococcaceae family in all the animals supplemented. Moreover, the
abundance of this family was increased in the PRE goup with respect to the REF group. Very
few data are available for this family and its modulation by diet, but it has been described
to be in lower proportion in diabetic people [79] or in a depression induced rat model [80].
In addition, PRE and P+P groups showed higher abundance of Clostridiaceae 1 family, in
the P+P group mainly due to the presence of Clostridium sensu stricto 1 genus as it was the
only group in which all animals presented this genus. In contrast with our results, neonatal
porcine supplemented with GOS showed a reduction in the abundance of Clostridium sensu
stricto 1 [81]. However, the higher abundance of these bacteria observed in our study due
to the prebiotic supplementation may be involving some positive effect in the intestinal
ecosystem because it is in line with lower abundance of this genus in diarrheal neonatal
piglets [82]. The prebiotic intervention, but not the postbiotic or the combination confirmed
the already described bifidogenic effect, which has also been described in previous studies
in rat pups [56] and infants [9,57,61,83]. It should be taken into account that the relative
abundances of bifidobacteria in this suckling rat model is much lower compared to the
bifidobacterial levels observed in an infant, thus the early life microbiota response to these
microbial-modulator products should be interpreted cautiously.
In our study, only the postbiotic group displayed Prevotellaceae and Muribaculaceae
families and the genus Prevotellaceae UCG-001, Erysipelatoclostridium, Lachnoclostridium,
Lachnoclostridium 5 and Ruminiclostridium 9 in all the animals supplemented. This particular
growth promoting effect is of importance in basis of the current literature. On the one hand,
the presence of Prevotellaceae in the microbiota of the postbiotic supplemented animals is
in line with the observation that the supplementation with only FOS in piglets induced a
higher relative abundance in Prevotella species, among others [73]. The healt promoting
effect of this change is based on the fact that Prevotellaceae UCG 001 is negatively correlated
with markers of glucose and lipid metabolism disorders [84], and that patients with chronic
Nutrients 2021, 13, 2975 17 of 22
kidney disease had lower Prevotellaceae UCG-001 than healthy controls [85]. However, a
spontaneous diabetes type 2 rat model showed higher levels of Prevotellaceae UCG-001
compared with healthy Wistar rats [86]. On the other hand, although the higher abundance
of Muribaculaceae in the POST group, which is described to be inversely associated with
body weight [87,88], no effect was found in this regard in the present study. With respect
to Lachnoclostridium, some species of this genus can protect mice against colitis [89], their
abundance is lower in gastrointestinal tract neoplasia [90], even though higher levels of
Lachnoclostridium were observed in adenoma [91]. Finally, Ruminiclostridium 9, also present
after the POST intervention, are SCFA-producing microbes [92] associated with body
weight regulation, obesity, inflammation and aging [92,93]. Overall, the biological relevance
of these changes induced by the postbiotic in this context should be further elucidated.
With regard to microbial functionality, SCFAs are the main products of microbial
fermentation in the gut and play an important role in the interaction between diet, gut
microbiota and host immune response [22,94]. SCFAs are considered anti-inflammatory
mediators [22] with regulatory roles in energy homeostasis, glucose and lipid metabolism,
and inulin sensitivity [31,37]. Although, none of the nutritional interventions modified the
total amount of SCFAs, some qualitative changes were observed in the animals receiving
the prebiotic mixture, alone or in combination with the postbiotic. Particularly, a profile
of SCFAs with lower proportion of propionic, isobutyric and isovaleric acid and higher
proportion of acetic acid was found. In accordance with our results, Frédéric Huet et al.
observed that the presence of scGOS/lcFOS in an infant formula modulated the children
microbiota and was associated with a change in SCFA pattern, which contained higher
proportion of acetate and a lower proportion of propionate and other SCFAs [57]. Moreover,
also in infants, the intestinal acetic acid production was increased in GOS supplemented for-
mula making the profile more similar to that found in breastfed infants [83]. In agreement
with our results, L. Beghin et al. also observed that isovaleric acid was reduced in infants
fed with a fermented infant formula supplemented with scGOS/lcFOS, although they also
observed changes in butyric acid [52] that we did not observe in our study. However, other
similar approaches in early life, such as those using GOS in piglets showed an increase in
butyric acid, among other changes [71,81].
To further study the changes observed in the relative abundances of gut microbiota
and the modification in the pattern of SCFA production, the two variables were correlated.
We observed that propionic acid production was correlated positively and negatively
with some bacterial families in agreement with the literature [69,95]. The present study
also showed some correlations regarding the acetic acid production, as described in other
studies [96–98], as well with isovalerate and isobutyrate [99,100]. Overall, these correla-
tions showed that the supplementation with scGOS/lcFOS and their combination with
Lactofidus™ changed the relative abundances of gut microbiota and consequently modified
the pattern of SCFA production.
5. Conclusions
The nutritional supplementation with the prebiotic (scGOS/lcFOS), the postbiotic
(Lactofidus™) and the combination of both, modulated the Ig profile, but the prebiotic mix-
ture and the postbiotic induced differential effects: whereas scGOS/lcFOS induced softer
feces and modulated microbiota composition and SCFA profile, Lactofidus™ upregulated
TLR gene expression. The use of the combination of scGOS/lcFOS and Lactofidus™ kept
both effects observed separately, but also showed a synergistic impact on animal growth.
Thus, the combined use of both products seems to be a good strategy to modulate immune
and microbial features in early life.
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